Genetics and the environment converge to dysregulate N-glycosylation in multiple sclerosis by Mkhikian, Haik et al.
ARTICLE

© 2011 Macmillan Publishers Limited. All rights reserved.
Received 2 Feb 2011 | Accepted 4 May 2011 | Published 31 May 2011 DOI: 10.1038/ncomms1333
How  environmental  factors  combine  with  genetic  risk  at  the  molecular  level  to  promote 
complex trait diseases such as multiple sclerosis (MS) is largely unknown. In mice, N-glycan 
branching by the Golgi enzymes Mgat1 and/or Mgat5 prevents T cell hyperactivity, cytotoxic 
T-lymphocyte antigen 4 (CTLA-4) endocytosis, spontaneous inflammatory demyelination and 
neurodegeneration, the latter pathologies characteristic of MS. Here we show that MS risk 
modulators converge to alter N-glycosylation and/or CTLA-4 surface retention conditional on 
metabolism and vitamin D3, including genetic variants in interleukin-7 receptor-α (IL7RA*C), 
interleukin-2 receptor-α (IL2RA*T), MGAT1 (IVAVT − T) and CTLA-4 (Thr17Ala). Downregulation 
of Mgat1 by IL7RA*C and IL2RA*T is opposed by MGAT1 (IVAVT − T) and vitamin D3, optimizing 
branching and mitigating MS risk when combined with enhanced CTLA-4 N-glycosylation by 
CTLA-4 Thr17. Our data suggest a molecular mechanism in MS whereby multiple environmental 
and genetic inputs lead to dysregulation of a final common pathway, namely N-glycosylation. 
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M
ultiple  sclerosis  (MS)  is  an  autoimmune  and  neurode-
generative disorder influenced by genetics, female gen-
der  and  vitamin  D3  (refs  1–3).  Molecular  mechanisms 
demonstrating  how  gene–gene  and  gene–environmental  interac-
tions  combine  to  regulate  disease  risk  remain  largely  unknown. 
Genome-wide association studies (GWAS) of common polymor-
phisms have identified only a proportion of the genetic variation 
responsible for familial disease clustering in complex trait diseases 
such as MS4, leading some to suggest that rare and highly penetrant 
variants account for the missing heritability5–8. However, rare and 
highly penetrant variants often display Mendelian type inheritance 
and are relatively insensitive to environmental influences (for exam-
ple, cystic fibrosis). An alternative is epistatic interactions9 between 
multiple independent alleles and the environment that affect a com-
mon biochemical pathway, whereby each factor has only a minor 
genetic  and/or  biological  effect,  but  when  combined  results  in 
severe deficiencies. Consistent with this, MS concordance rates in 
monozygotic twins are only ~30% (ref. 10), despite recent evidence 
that discordant twins do not harbour significant sequence differ-
ences in their genome, epigenome and transcriptome11. This implies 
direct environmental impact on genetic risk.
Virtually  all  cell  surface  and  secreted  proteins  in  metazoans 
are modified by co- and/or post-translational addition of complex 
carbohydrates in the endoplasmic reticulum/Golgi secretory path-
way12,13, providing information encoding distinct from the genome14. 
Unlike DNA/RNA/protein, production of complex carbohydrates 
is not template driven, but rather is controlled by the activity of 
endoplasmic  reticulum/Golgi  enzymes  and  metabolic  supply  of 
their substrates. The branching and number of N-glycans per pro-
tein molecule cooperate to regulate binding to galectins, forming 
a molecular lattice at the cell surface that controls the concentra-
tion and endocytosis of surface glycoproteins14. N-Glycan number is 
gene-encoded while branching is conditional to activity of the Golgi 
α-mannosidases, N-acetylglucosaminyltransferases I, II, IV and V 
(Mgat1, 2, 4 and 5) and hexosamine pathway production of the sub-
strate uridine diphosphate N-acetylglucosamine (UDP-GlcNAc)15,16 
(Fig. 1a). In mice, genetic deficiencies in N-glycan branching pro-
mote  neurodegeneration,  spontaneous  inflammatory  demyelina-
tion, T cell receptor (TCR) clustering/signalling, T helper 1 (TH1) 
differentiation and endocytic loss of the growth and autoimmune 
inhibitor cytotoxic T-lymphocyte antigen 4 (CTLA-4), phenotypes 
that can be reversed by metabolic supplementation to UDP-GlcNAc 
biosynthesis15–21.
In this study, we investigate whether similar mechanisms are 
active in MS through detailed biological characterization of known 
polymorphisms and a unique candidate gene approach. Our data 
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Figure 1 | IL-2 and IL-7 signalling regulate N-glycan branching in T cells. (a) Hexosamine and N-glycan branching pathway in mammals. Medial Golgi 
enzymes Mgat1, 2, 4a/b, and 5 generate mono-, bi-, tri- and tetra-antennary branched N-glycans, respectively, in a sequential manner that is dependent 
on the supply of a common substrate, UDP-GlcNAc. GlcNAc branches are further modified to create N-acetyllactosamine units, which serve as binding 
sites for galectins and L-PHA. Mgat1, 2, 4 and 5, N-acetylglucosaminyltransferases I, II IV and V; MII/MIIx, mannosidase II/IIx, MIa,b,c, mannosidase 
I,a,b,c; SW, swainsonine. Additional structural diversity by addition of sialic acid, fucose, N-acetylgalactosamine and/or sulphate is not shown12.  
(b) Resting human PBMCs were treated for 3 days as indicated and analysed for L-PHA binding by fluorescence-activated cell sorting, gating on 
CD4 + CD25 −  resting populations based on forward versus side scatter. MFI for control cells was used to normalize data. (c) Resting mouse splenocytes 
with the indicated genotypes were treated with IL-2 (20 ng ml − 1) and analysed as in b. (d) Quantitative reverse transcription PCR on cDNA derived from 
resting human CD3 +  T cells treated with IL-2 (20 ng ml − 1) in triplicate. (e) Resting Human PBMCs were treated with IL-7 (20 ng ml − 1) and analysed as in 
d. Genotypes for human cells were IL2RA*TC and IL7RA*CC except for d, which was IL2RA*TT. P values by analysis of variance and the Newman–Keuls 
Multiple Comparison Test. ***P < 0.001, **P < 0.01 in all panels. Error bars are standard error of triplicate or greater values in all panels.ARTICLE     
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suggests that N-glycosylation provides the first unifying molecular 
mechanism  in  MS,  whereby  convergent  genetic  dysregulation  is 
modulated by multiple environmental inputs such as metabolism 
and sunlight/vitamin D3.
Results
IL-2 and IL-7 regulate T cell growth via N-glycan branching. 
Interleukin-2  receptor  (IL-2R)  and  interleukin-7  receptor  (IL-
7R)  are  members  of  the  common  γ  chain  cytokine  receptor 
family  and  use  signal  transduction  through  Stat5.  Recently, 
genetic alterations in the IL-2 and IL-7 signalling pathways have 
been implicated in MS3,22,23. To examine whether these pathways 
alter  N-glycan  branching,  we  used  flow  cytometry  with  L-PHA 
(Phaseolus  vulgaris,  leukoagglutinin),  a  plant  lectin  that  binds 
specifically  to  β1,6GlcNAc-branched  N-glycans,  the  product 
of  Mgat5  (Fig.  1a)18,24.  Addition  of  exogenous  IL-2  or  IL-7   
to  resting  human  T  cells  reduced  L-PHA-binding  structures 
(hereafter termed as branching) in CD25 − CD4 +  T cells by ~20–30%  
(Fig.  1b  and  Supplementary  Fig.  S1a).  Analysis  of  IL-2  and   
IL-7RA deficient ex vivo CD25 − CD4 +  mouse T cells revealed ~50% 
and  > 2-fold increases in branching, respectively, confirming that 
autocrine  IL-2  and  IL-7  signalling  regulates  branching  in  vivo  
(Fig. 1c). As ~15–20% change in L-PHA binding is sufficient to alter 
T cell function, growth and autoimmune risk16,20, these alterations 
are highly significant and in the case of IL-7RA deficiency, represents 
the largest change observed outside of direct manipulation of the 
Golgi branching pathway. Indeed, addition of exogenous IL-2 or   
IL-7 both induce ~2-fold increase in the Golgi MGAT1 mRNA as   
well as ~1.5–3-fold decreases in Golgi MGAT5, MGAT4B, manno-
sidase II and IIx (MAN2A1, MAN2A2) and mannosidase Ia and b 
(MAN1A1, MAN1A2; Fig. 1d,e). These mRNA changes are opposite 
of that induced by TCR signalling, which enhances branching25. 
Mgat1 has a ~250-fold higher affinity for UDP-GlcNAc than Mgat5 
and  over  expression  of  Mgat1,  particularly  in  the  presence  of 
reduced Mgat4 and Mgat5, decreases branching by limiting UDP-
GlcNAc supply to Mgat4 and Mgat5 (refs 15, 25).
T cell activation enhances branching as well as IL-2 and IL-2RA 
expression; therefore, we next examined the effects of IL-2 and IL-7 
signalling in T cell blasts. Exogenous IL-2 enhanced TCR signal-
ling-induced  increases  in  branching  in  CD25 + CD4 +   mouse  and 
human T cell blasts, whereas anti-IL-2 neutralizing antibody, the 
IL-2RA antagonist Ro26-4550 and/or IL-2 deficiency had the oppo-
site effect (Fig. 2a and Supplementary Fig. S1b). Similarly, addition 
of  exogenous  IL-7  increased  branching  in  human  CD25 + CD4 +   
T cell blasts, whereas deficiency of IL-7RA limited upregulation of 
branching in mouse CD25 + CD4 +  T cell blasts (Fig. 2b and Supple-
mentary Fig. S1b). IL-2 treatment significantly enhanced transcripts 
of  MGAT1 > MAN2A2 > MGAT5  in  TCR-activated  CD25 + CD3 +   
T cells (Supplementary Fig. S1c). These data are consistent with 
the  ultra-sensitive  kinetics  of  the  Golgi  branching  pathway15,  in 
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Figure 2 | IL2RA*T and IL7RA*C MS risk alleles limit N-glycan branching in T cell blasts. (a) Human CD3 +  T cells or mouse splenocytes were stimulated 
with anti-CD3 (200 ng ml − 1) and treated as indicated for 5 days. CD25 + CD4 +  T cell blasts were analysed for L-PHA binding by fluorescence-activated 
cell sorting (FACS). Ro26-4550 is an IL-2RA antagonist. (b) Human T cells were stimulated with anti-CD3 (200 ng ml − 1) and treated as indicated for 
5 days. CD25 + CD4 +  T cell blasts were analysed as in a. (c) Purified human T cells were pre-treated for 3 days with IL-2 (20 ng ml − 1) and/or GlcNAc 
(40 mM) + uridine (10 mM), and then stimulated with anti-CD3 for 24 h. CD4 +  T cells were analysed for CD69 expression and L-PHA binding by FACS.  
(d) Mouse splenocytes with the indicated genotypes were stimulated with anti-CD3 for 24 h. CD4 +  T cells were analysed as in c. (e) Human T cells or 
mouse splenocytes were stimulated with anti-CD3 (200 ng ml − 1) and treated with anti-IL2 (20 µg ml − 1) or sIL2RA (5 µg ml − 1) for 5 days. CD25 + CD4 +  T 
cell blasts were analysed for CTLA-4 surface expression. Data are normalized to control and by subtracting background from unstimulated CD4 +  T cells. 
(f) Mouse splenocytes with the indicated genotypes were stimulated with anti-CD3 for 5 days, with or without IL-2 (20 ng ml − 1) and/or SW (150 nM) 
addition at day 3. CD25 + CD4 +  T cell blasts were analysed for CTLA-4 surface expression as in e. (g) Human CD25 + CD4 +  T cells were stimulated 
with anti-CD3 (200 ng ml − 1) and treated with sIL2RA (12.5 µg ml − 1) and/or sIL7RA/Fc (50 µg ml − 1) for 3 days. Relative mRNA levels were measured by 
quantitative reverse transcription PCR (normalized to actin). (h) Human T cells (IL7RA*CC) with the indicated genotypes were stimulated with anti-CD3 
(200 ng ml − 1) for 2–6 days, with or without sIL2RA (12.5 µg ml − 1). CD25 + CD4 +  T cell blasts were analysed for L-PHA binding by FACS as in a. Genotypes 
were IL2RA*CC and IL7RA*CC in a; IL2RA*CT and IL7RA*CT in b, e and g; IL2RA*CT and IL7RA*CT in c and d; all lacked the MGAT1 IVAVT − T haplotype.  
P values by analysis of variance and the Newman–Keuls Multiple Comparison Test. ***P < 0.001, **P < 0.01, *P < 0.05 in all panels. Error bars are standard 
error of triplicate or greater values in all panels.ARTICLE
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which  MGAT1  hyperactivity  limits  branching  in  resting  T  cells 
with low UDP-GlcNAc and Mgat5 activity, but enhances branching   
in T cell blasts where UDP-GlcNAc, Mgat5 and mannosidase IIx 
are  enhanced.  CD25  is  also  constitutively  expressed  by  FoxP3 +   
T regulatory cells; however, IL-2 enhanced branching to a much 
greater extent in CD25 + FoxP3 −  T cell blasts (Supplementary Fig. 
S1d). Thus, IL-2 and IL-7 co-regulate multiple Golgi genes to reduce 
branching in resting T cells; but promote branching in T cell blasts.
Cytokine-induced alterations in branching are expected to ini-
tially  promote  TCR-mediated  growth18,  followed  by  enhanced 
growth arrest of T cell blasts by increased CTLA-4 surface expres-
sion15.  Indeed,  pretreatment  of  resting  human  T  cells  with  IL-2 
significantly  enhanced  TCR  signalling-mediated  upregulation  of 
CD69 in the absence but not presence of N-acetylglucosamine (Glc-
NAc) and uridine (Fig. 2c). GlcNAc and uridine enhance branch-
ing by increasing UDP-GlcNAc supply to the Golgi15,16, and rescued 
reductions induced by IL-2 (Fig. 2c inset). Similarly, analysis of 
IL7RA − / − Mgat5 − / −  double knockout mice revealed that suppression 
of TCR activation by IL7RA deficiency requires Mgat5 (Fig. 2d). In 
CD25 + CD4 +  T cell blasts, anti-IL-2 neutralizing antibody and IL-2 
deficiency reduced CTLA-4 surface expression (Fig. 2e,f), the latter 
reversed by the addition of exogenous IL-2 in the absence but not 
presence of swainsonine (SW; Fig. 2f). SW is an inhibitor of Golgi 
α-mannosidase II/IIx that reduces branching downstream of Mgat1 
(Fig. 1a)26, confirming that IL-2 promotes CTLA-4 surface retention 
by increasing branching.
IL2RA and IL7RA MS risk alleles reduce MGAT1 and branching. 
The IL2RA*T (rs2104286) and IL7RA*C (rs6897932) MS risk alleles 
are the common alleles in Caucasian populations (frequency ~75%) 
and are associated with enhanced secretion of soluble receptors (that 
is, sIL2RA and sIL7RA) that bind cognate cytokines and antagonize 
signalling  (Supplementary  Fig.  S2a–c)22,27–29.  Exogenous  sIL2RA 
and sIL7RA/Fc chimera both reduced branching in CD25 + CD4 +   
T cell blasts, an effect that was additive when combined and rescued 
by exogenous IL-7 or GlcNAc (Fig. 2a,b). Blocking IL-2 and IL-7 
signalling with sIL2RA and sIL7RA or anti-IL-2 and anti-IL-7 neu-
tralizing antibodies both reduced MGAT1 mRNA in CD25 + CD4 +  
T cell blasts, yet had little effect on MGAT5 expression (Fig. 2g and 
Supplementary Fig. S2d). sIL2RA reduced CTLA-4 surface levels 
in T cell blasts to a similar degree as anti-IL-2 neutralizing anti-
body (Fig. 2e). Directly comparing T cell blasts with or without   
the IL2RA*T risk allele revealed minimal differences in branch-
ing during early stages of activation; however by day 6, branch-
ing in IL2RA*TT and IL2RA*TC blasts was significantly reduced 
relative  to  IL2RA*CC  blasts  (Fig.  2h,  Supplementary  Fig.  S2e), 
consistent with enhanced endogenous sIL2RA production by the   
T allele. Addition of exogenous sIL2RA to IL2RA*CC T cell cultures 
lowered branching at day 6 to that observed in IL2RA*TT blasts   
(Fig. 2h), confirming differences in branching arose from reduced 
endogenous sIL2RA in IL2RA*CC T cell cultures. Thus, soluble 
receptors associated with the IL2RA*T and IL7RA*C risk alleles 
combine to downregulate MGAT1 and branching in T cell blasts.
MGAT1  variants  alter  branching  conditional  on  metabolism. 
Next, we directly screened the MGAT1 gene for functional variants. 
Sequencing the MGAT1 coding region (exon 2) in 42 MS patients 
identified a high frequency of variants suitable for functional test-
ing (Supplementary Fig. S3a). The direct cloning of PCR-amplified 
genomic DNA revealed multiple haplotypes that rescued cell surface 
binding to L-PHA when transiently transfected into Lec1 cells30, an 
Mgat1-deficient Chinese Hamster Ovary cell line (Fig. 3a and Sup-
plementary Fig. S3b,c). All variant haplotypes were less effective 
than the common haplotype, with those harbouring both the IV A 
(rs7726005) and VT − T (rs2070924 and rs2070925) polymorphisms 
reducing branching ~20%. The IV A and VT − T polymorphisms seem 
to exert additive effects, as separately each displayed a ~10% reduc-
tion in branching. Consistent with this, anti-CD3 and myelin-acti-
vated T cells heterozygous for the IV A and VT − T polymorphisms 
(hereafter  referred  as  the  MGAT1  IV AVT − T  haplotype)  displayed 
reduced upregulation of branching (Fig. 3b,c). Transient transfec-
tion into Lec1 cells demonstrated that the IV A, VT − T and IV AVT − T 
haplotypes  increased  Mgat1  activity  ~2-,  2-  and  3-fold,  respec-
tively, a phenotype also associated with peripheral blood mono-
nuclear cells (PBMCs) harbouring the MGAT1 IV AVT − T haplotype 
(Fig.  3d,e).  Matrix-assisted  laser  desorption/ionization–time  of 
flight mass spectroscopy confirmed the N-glycan product of Mgat1 
(mono-antennary) was increased relative to its N-glycan acceptor 
(Man5GlcNAc2)  in  PBMCs  with  the  MGAT1  IV AVT − T  haplotype 
(Fig. 3f and Supplementary Fig. S3d).
The MGAT1 IV AVT − T haplotype harbours three polymorphisms 
in exon 2: an upstream non-synonymous coding single-nucleotide 
polymorphism (SNP; IV A: G1164A encoding Arg223Gln) and two 
synonymous  coding  SNPs  that  are  ten  nucleotides  apart  (VT − T: 
C1637T and G1648T). On the basis of the Mgat1 enzyme crystal 
structure,  Arg223Gln  is  a  surface-exposed  residue  far  from  the 
active site and therefore unlikely to effect enzyme activity31. How-
ever, IV A increased MGAT1 mRNA levels relative to the common 
haplotype in Lec1-transfected cells (Fig. 3g). The two synonymous 
SNPs in VT − T , with or without IV A, also increased mRNA expres-
sion following transfection, although with differing kinetics. Analy-
sis of heterozygous PBMCs confirmed mRNA levels of the MGAT1 
IV AVT − T haplotype were ~2-fold higher than the common haplotype 
in vivo (Fig. 3h).
The Km of Mgat5 for UDP-GlcNAc is significantly higher than 
Mgat1 (~11 versus ~0.04 mM), whereas this difference is reversed 
for their respective N-glycan acceptors (~0.087 versus ~2 mM)15. 
The  ~2-  to  3-fold  increase  in  Mgat1  expression  induced  by  the 
MGAT1  IV AVT − T  haplotype  increased  Mgat1  product  (Fig.  3f) 
while also reducing UDP-GlcNAc supply to downstream Mgat5. 
The latter is predicted to reduce β1,6GlcNAc branching by Mgat5, 
and indeed, this was observed both experimentally (Fig. 3a,b) and 
with computational modelling (Fig. 4a)15. Thus, MGAT1 IV AVT − T 
functions dominantly to reduce branching under basal UDP-Glc-
NAc levels, but with increasing UDP-GlcNAc and/or Mgat5 levels, 
enhanced Mgat1 expression is expected to become less effective in 
limiting supply of UDP-GlcNAc to Mgat5, thereby allowing Mgat5 
to act on the increased supply of N-glycan acceptors from Mgat1 
to  first  equalize  and  then  super-rescue  β1,6GlcNAc  branching. 
Indeed, these pathway dynamics were revealed by computational 
modelling (Supplementary Fig. S4a) and confirmed experimentally 
by increasing UDP-GlcNAc levels in transiently transfected Lec1 
cells and CD4 +  T cells by GlcNAc supplementation (Fig. 4b and   
Supplementary  Fig.  S4b).  Consistent  with  this  model,  the  mag-
nitude of super-rescue by GlcNAc for the IV A, VT − T and IV AVT − T  
haplotypes was proportional to baseline enzyme activities. Thus, the 
gain-of-function  haplotypes  of  MGAT1-reduce  branching  under 
basal  conditions,  but  enhance  levels  when  UDP-GlcNAc  and/or 
Mgat5 are increased above a threshold.
Consistent with reduced branching, resting PBMCs heterozygous 
for  the  MGAT1  IV AVT − T  haplotype  were  more  sensitive  to  TCR   
agonist than cells homozygous for the common MGAT1 haplotype 
(Fig. 4c). Blocking the branching with SW enhanced proliferation 
of cells with the common MGAT1 haplotype, but had little effect 
on cells heterozygous for the MGAT1 IV AVT − T haplotype, the latter 
consistent with the pre-existing deficiency in branching (Fig. 4c).
The Thr17Ala polymorphism in human CTLA-4 encodes a non-
synonymous  SNP  (49A/G,  rs231775)  in  the  signal  peptide  that 
reduces average N-glycan occupancy at the two N-X-S/T sites from 
two to one, limiting CTLA-4 surface levels and promoting T cell 
proliferation32,33. Such alterations in N-glycan number are expected 
to interact with the MGAT1 IV AVT − T haplotype to control CTLA-4 ARTICLE     
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surface expression15. Indeed, computational modelling, co-transfec-
tion of Lec1 cells and analysis of T cell blasts confirmed previous 
observations32,33 of significantly lower surface CTLA-4 Ala17 (that 
is, one N-glycan) compared with CTLA-4 Thr17 (that is, two N-
glycans) when co-expressed with the common MGAT1 haplotype   
(Fig. 4d and Supplementary Fig. S4c–e). The MGAT1 IV AVT − T haplo-
type also limited CTLA-4 surface levels when expressed with the 
common CTLA-4 Thr17 allele (two N-glycans) whereas combining 
the MGAT1 IV AVT − T haplotype with CTLA-4 Ala17 (one N-glycan) 
further  reduced  CTLA-4  surface  levels.  These  phenotypes  were   
rescued by increasing UDP-GlcNAc levels and/or GlcNAc supple-
mentation, confirming that these phenotypes are sensitive to metabo-
lism. GlcNAc also inhibited proliferation of T cells heterozygous for 
the MGAT1 IV AVT − T haplotype (Supplementary Fig. S4f).
Soluble receptors associated with the IL2RA*T and IL7RA*C MS 
risk alleles reduce Mgat1 mRNA and should interact with Mgat1 
upregulation by the MGAT1 IV AVT − T haplotype to control branch-
ing (Fig. 4a). Indeed, addition of exogenous IL-2 or IL-7 enhanced 
branching in control cells but reduced branching in MGAT1 IV AVT − T 
heterozygous cells (Fig. 4e, interaction P = 1.7×10 − 5). These results 
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Figure 3 | MGAT1 haplotypes reduce N-glycan branching. (a) MGAT1 exon 2 was amplified by PCR from genomic DNA, cloned into the pCMV vector, 
sequenced to identify haplotypes, transiently transfected into Mgat1-deficient CHO cells (Lec1) in triplicate and analysed 3 days later by L-PHA 
fluorescence-activated cell sorting. MFI was determined on the L-PHA +  population and normalized to the common haplotype (WT). (b) Anti-CD3 or (c) 
myelin peptide was used to stimulate PBMCs from healthy human controls for 48 h. Fold increase in L-PHA MFI in CD4 +  T cells following stimulation 
was determined by comparing unstimulated resting cells with blasting cells in each subject. All subjects had ≥3 IL2RA*T + IL7RA*C risk alleles, except one 
subject in each group heterozygous for both. (d) Mgat1-deficient Lec1 cells were transiently transfected with the indicated MGAT1 haplotypes and lysed 
to assess Mgat1 enzyme activity. Average Mgat1 activity for WT (common haplotype) was 6.45 nmol mg − 1 h − 1. Activities were normalized for transfection 
efficiency. (e) Human PBMCs with the indicated genotypes (n = 4 per genotype) were lysed to assess Mgat1 enzyme activity as in d. Subjects had ≥3 
IL2RA*T + IL7RA*C risk alleles. (f) N-Glycans in human PBMCs with the indicated genotypes (n = 6 per genotype) were analysed by matrix-assisted laser 
desorption/ionization–time of flight mass spectroscopy and normalized by taking the ratio of the intensity of mono-antennary ((Gal)GlcNAc1Man5GlcNAc2)  
to Man5GlcNAc2, the product and acceptor of Mgat1, respectively. Subjects had ≥ 3 IL2RA*T + IL7RA*C risk alleles except for two MGAT1 IVAVT − T subjects 
that were double heterozygotes; removal of which does not alter the result (that is, 2.01 versus 1.97). (g) Lec1 cells transfected with the indicated MGAT1 
haplotypes were analysed for relative mRNA levels by quantitative reverse transcription PCR. Expression was normalized for transfection efficiency. (h) 
Human PBMCs from two heterozygous MGAT1 IVAVT − T subjects were examined for differential allelic expression by comparing the relative abundance 
of mRNA and genomic DNA (gDNA) for each haplotype in vivo. P values in b, c, e, f and h by t-test and panels a, d and g by analysis of variance and the 
Newman–Keuls Multiple Comparison Test. *P < 0.05, **P < 0.01, ***P < 0.001 in all panels. Error bars are standard error of triplicate or greater values in  
all panels.ARTICLE
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were predicted by computational modelling, with upregulation of 
Mgat1 by IL-2 or IL-7 enhancing or reducing branching depending 
on baseline Mgat1 activity (Fig. 4a).
Taken together, these data indicate that the MGAT1 IV AVT − T hap-
lotype lowers branching, T cell activation thresholds and CTLA-4 
surface retention in a manner that is sensitive to metabolic con-
ditions (that is, UDP-GlcNAc), activity of other Golgi branching 
enzymes (for example, Mgat5), the number of N-glycans attached to 
CTLA-4 (that is, CTLA-4 Thr17Ala) and IL-2 and IL-7 signalling.
Genetic interactions in MS.  The  biological  interactions  defined 
above for IL2RA (rs2104286), IL7RA (rs6897932), MGAT1 IV AVT − T 
(rs7726005,  rs2070924  and  rs2070925)  and  CTLA-4  Thr17Ala 
(rs231775) are expected to result in genetic interaction in MS. To   
test this hypothesis, we first examined point association of the four 
variants in two Caucasian MS case–control cohorts from North 
America  (n = 2,705  and  n = 9,132,  respectively).  We  replicated 
association of IL2RA (rs2104286) and IL7RA (rs6897932) as well 
as the lack of association of CTLA-4 (rs231775) in both cohorts 
(Table  1,  Supplementary  Table  S1)3,22,23,34.  Although  the  MGAT1 
IV AVT − T haplotype is relatively rare (carrier frequency ~7.2%), we 
observed a novel association for carrier status in both cohorts, with 
P = 1.51×10 − 5 and odds ratio (OR) = 1.36 in combined data of 3,280 
cases and 8,557 controls (Table 1, Supplementary Table S1). Allelic 
analysis yielded a trend P value (Cochran–Armitage) of 1.90×10 − 5 
(1 tail) for combined data. Pearson’s correlation (r) confirmed that 
the  IV A  (rs7726005)  and  VT − T  (rs2070924  and  rs2070925)  poly-
morphisms  are  in  strong  linkage  disequilibrium  (r = 0.633695, 
P < 2.2×10 − 16), as first observed by physical cloning and sequenc-
ing of genomic DNA (Fig. 3a). Analysis of the IV A and VT–T poly-
morphisms irrespective of haplotype revealed association of VT–T 
(rs2070924 and rs2070925; P = 1.67×10 − 4, OR = 1.29) and marginal 
association  of  IV A  (rs7726005,  P = 1.66×10 − 2,  OR = 1.13  (Supple-
mentary Table S1)).
As gene–gene interaction analysis requires large sample sizes 
(power calculations in Table 1), especially when alleles are rare, 
we  conducted  stratified  analysis  in  both  Caucasian  cohorts  and 
interaction analyses only in combined data. Consistent with oppos-
ing effects on Mgat1 that optimize enzyme activity and branching 
when combined, stratified analysis of the Caucasian data reveals 
that MGAT1 IV AVT − T significantly increases MS risk when there 
are less than four copies of the IL2RA*T and IL7RA*C risk alleles 
(P = 3.60×10 − 5, OR = 1.45), whereas no association was observed in 
the presence of four copies of the IL2RA*T and IL7RA*C (P = 0.195, 
OR = 1.13; Table 1, Supplementary Table S2). The P value for inter-
action is 6.75×10 − 2.
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Next, we tested for interaction of MGAT1 IV AVT − T with CTLA-4 
Thr17Ala (rs231775). CTLA-4 Thr17 harbours twice as many N-glycans 
as CTLA-4 Ala17 and therefore should compensate for reduced branch-
ing by MGAT1 IV AVT − T to mitigate MS risk. Indeed, MGAT1 IV AVT − T sig-
nificantly associated with MS in CTLA-4 Ala17 carriers (P = 4.95×10 − 6, 
OR = 1.53), but not CTLA-4 Thr/Thr homozygotes (P = 0.329, OR = 1.06) 
with an interaction P value of 1.20×10 − 2 (Table 1, Supplementary Table 
S2). Stratifying the data based on six or less than six alleles of CTLA-
4 Thr17, IL2RA*T and IL7RA*C strengthened the interaction, with 
MGAT1 IV AVT − T-promoting MS in the latter (P = 1.62×10 − 6, OR = 1.46), 
whereas  appearing  to  be  protective  in  the  former  (P = 4.08×10 − 2, 
OR = 0.64), giving an interaction P value of 9.48×10 − 4.
Finally,  we  examined  an  independent  African-American  MS 
cohort (758 cases, 480 controls). On the basis of HapMap data, 
IL2RA*T  and  IL7RA*C  risk  alleles  are  much  more  common  in   
Sub-Saharan Africans/African-Americans (risk allele frequencies of 
~0.90–0.95 versus ~0.75 in Caucasians). Indeed, analysis of a subset 
of the African-American MS cases (n = 478) revealed IL2RA*T and 
IL7RA*C allele frequencies of 0.94 and 0.88, respectively. As these 
high frequencies limit power, we restricted further analysis of the 
African-American cohort to MGAT1 IV AVT − T and CTLA-4 Thr17Ala. 
MGAT1 IV AVT − T did not display association in African-American 
MS (P = 0.215), with an OR similar to Caucasians with IL2RA*T  +   
IL7RA*C = 4 (that is, 1.15 versus 1.13, respectively), a result consist-
ent with the much higher frequencies of IL2RA*T and IL7RA*C in 
African-Americans (Table 1). However, stratifying the data based on 
CTLA-4 Thr17Ala replicated the Caucasian MS data, with MGAT1 
IV AVT − T-promoting MS in CTLA-4 Ala17 carriers (P = 8.40×10 − 3, 
OR = 1.82),  but  appearing  to  be  protective  in  CTLA-4  Thr/Thr 
homozygotes (P = 4.95×10 − 2, OR = 0.64), with an interaction P value 
of 2.29×10 − 3. The OR in CTLA-4 Thr/Thr homozygotes is similar to 
that in Caucasians with six alleles of CTLA-4 Thr17, IL2RA*T and 
IL7RA*C (that is, 0.64 and 0.64, respectively), again consistent with 
the much higher frequencies of IL2RA*T and IL7RA*C in African-
Americans. Combining the African-American and Caucasian P val-
ues gives P = 7.48×10 − 7 for CTLA-4 Ala17 carriers and P = 3.16×10 − 4 
for  interaction.  Importantly,  this  interaction  is  observed  despite 
lack of point association and marginal effects of CTLA-4 Thr17Ala 
in both the Caucasian and African-American data, indicating an   
epistatic  interaction.  Thus,  the  Caucasian  and  African-American 
MS  data  are  concordant  and  when  combined  with  the  demon-
strated  biological  interactions,  provide  strong  evidence  that  the 
four variants converge on N-glycosylation to differentially regulate   
MS risk.
Table 1 | Genetic interaction in multiple sclerosis.
Ethnicity Variant frequency P value OR (95% CI)
Control (n) MS (n)
IL2RA*T 
(rs2104286) Caucasian 0.740 (6507) 0.770 (3168) 2.44×10 − 6 1.18 (1.10–1.26)
IL7RA*C 
(rs6897932 ) Caucasian 0.747 (6506) 0.767 (3172) 1.05×10 − 3 1.12 (1.04–1.20)
CTLA-4*Thr17  
(rs237155) 
Caucasian 0.613 (6506) 0.620 (3173) 0.184 1.03 (0.97–1.09)
African-American 0.639 (480) 0.642 (758) 0.453 1.01 (0.86–1.20)
MGAT1IVAVT–T
Caucasian 0.0713 (8557) 0.0942 (3280) 1.51×10 − 5 1.36 (1.17–1.56)
African-American 0.110 (480) 0.125 (758) 0.215 1.15 (0.81–1.65)
Stratified analysis
Ethnicity MGAT1 IVAVT-T frequency P value OR (95% CI) Interaction  
P value (empiric  
P value, power) Control (n) MS (n)
IL2RA*T   
+ IL7RA*C
   <4 
Caucasian
0.0708 (4491) 0 0993 (2084) 3.60×10 − 5 1.45 (1.21–1.74) 6.75×10 − 2  
(7.1×10 − 2, 0.32)      =4 0.0744 (2015) 0.0831 (1083) 0.206 1.13 (0.86–1.48)
CTLA-4*Thr17
   < 2
Caucasian
0.0707 (4031) 0.104 (1940) 4.95×10 − 6 1.53 (1.26–1.85)
1.20×10 − 2  
(1.3×10 − 2, 0.62)  
      =2 0 0746 (2465) 0.0787 (1232) 0.329 1.06 (0.82–1.37)
      < 2
African- 
American
0.0860 (279) 0.146 (438) 8.40×10 − 3 1.82 (1.11–2.98)
2.29×10 − 3  
(2.5×10 − 3, 0.81)
       =2 0.144 (201) 0.0969 (320) 4.95×10 − 2 0.64 (0.37–1.10)
Combined P values:  < 2 7.48×10 − 7 3.16×10 − 4
IL2RA*T  +  
IL7RA*C  +   
CTLA-4*Thr17
   < 6
Caucasian
0.0712 (5732) 0.101 (2754) 1.62×10 − 6 1.46 (1.24–1.71)
9.48×10 − 4  
(9×10 − 4, 0.87)
      =6 0.0791 (771) 0.0523 (421) 4.08×10 − 2 0.64 (0.39–1.06)
CI, confidence intervals ; OR, odds ratio.
Combined data from two independent North American Caucasian case–control MS cohorts and an African-American MS cohort. Reported is one-sided P values computed using the Cochran-Armitage 
test with MGAT1 IVAVT–T (rs7726005, r2070924 and rs2070925) coded 0 or 1 for carrier status and IL2RA*T (rs2104286), IL7RA*C (rs6897932) and CTLA-4 Thr17 (rs231775) coded as 0, 1 or 2 for the 
number of alleles. MGAT1 IVAVT–T homozygosity is 0.0016 and 0.0021 for Caucasian controls and MS, respectively. Compound heterozygosity for the IVA and VT–T variants is estimated at ~1 in 5,800 in 
Caucasians; therefore, subjects genotyped as heterozygous for both are treated as the MGAT1 IVAVT–T haplotype. All control cohorts are in Hardy-Weinberg Equilibrium. ARTICLE
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Vitamin D3 enhances Mgat1 to inhibit demyelinating disease. 
Deficiency of vitamin D3, which is synthesized from 7-dehydrocho-
lesterol in the skin on ultraviolet sun exposure, strongly associates 
with MS2,35,36. Vitamin D3 and/or its active metabolite 1α,25-dihy-
droxyvitamin D3 (1,25(OH)2D3) inhibit T cell activation37, inter-
feron-γ production38 and T cell-mediated demyelinating disease38; 
however, molecular mechanisms are unclear. 1,25(OH)2D3 enhanced 
MGAT1  mRNA  levels  in  human  male  and  female  CD4 + CD25 +  
T cell blasts, a phenotype similar to the MGAT1 IV AVT − T haplo-
type but opposite of the IL2RA*T + IL7RA*C risk alleles (Fig. 5a). 
1,25(OH)2D3 also increased MAN1A1, but had little effect on other 
Golgi branching genes. In the presence of the IL2RA*T and IL7RA*C 
risk alleles, 1,25(OH)2D3 should enhance branching by reversing 
Mgat1 downregulation resulting from reduced IL-2 and IL-7 signal-
ling. In contrast, upregulation of Mgat1 by 1,25(OH)2D3 in T cell 
blasts lacking the IL2RA*T and IL7RA*C risk alleles is expected to   
have little or negative effect. Indeed, although 1,25(OH)2D3 enhanced 
branching in T cell blasts with two or more copies of the IL2RA*T 
and IL7RA*C risk alleles (Fig. 5b), branching was unchanged or 
reduced  (depending  on  TCR  stimulation  strength)  in  blasting   
T  cells  homozygous  for  both  protective  alleles  (Fig.  5c  and   
Supplementary Fig. S5). Addition of exogenous sIL2RA and sIL7RA   
to the latter cells, thereby mimicking the IL2RA*T and IL7RA*C   
risk alleles, restored the ability of 1,25(OH)2D3 to enhance branch-
ing (Fig. 5c). As a very small minority of Caucasians are homo-
zygous for the IL2RA*C and IL7RA*T protective alleles (~0.5%), 
vitamin D3 is expected to promote branching in the majority of   
the population.
T cells from the PL/J mouse strain are deficient in Mgat1 activity 
(that is, ~3.3 versus 5.57 nmol mg − 1 h − 1 in 129/Sv) and branching20, 
providing a model for Mgat1 deficiency similar to the IL2RA*T 
and IL7RA*C MS risk alleles. The vitamin D3 receptor is minimally 
expressed in naive ex vivo T cells and upregulated by TCR or vita-
min D3 signalling39. Addition of 1,25(OH)2D3 to resting PL/J mouse 
or human T cells had little affect on branching (Supplementary 
Fig. S6a,b), whereas addition to TCR-activated female PL/J mouse 
T cells enhanced branching (Supplementary Fig. S6c). Consistent 
with previous observations that 1,25(OH)2D3 inhibits experimen-
tal autoimmune encephalomyelitis (EAE) in C57BL/6 female but 
not male mice, 1,25(OH)2D3 had minimal effects on branching in 
male PL/J mouse T cell blasts (Supplementary Fig. S6d); however, 
both male and female human T cell blasts responded similarly with 
enhanced branching (Supplementary Fig. S6e,f). C57BL/6 mice are 
also deficient in Mgat1 activity, however, branching is reduced to a 
much smaller degree than PL/J mice20. Reducing dietary supply of 
vitamin D3 in female PL/J mice decreased branching in CD4 +  T cells 
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Figure 5 | Vitamin D3 counters IL2RA*T- and IL7RA*C-mediated reduction in Mgat1 to promote N-glycan branching. (a) Male (right) or female (left) 
purified human CD4 +  T cells were pre-stimulated with plate-bound anti-CD3 for 4 days (1 µg ml − 1) then treated with 100 nM 1,25(OH)2D3 for 3, 6 and 9 h. 
Blasting CD25 +  T cells were isolated and collected for mRNA extraction and cDNA synthesis. Relative mRNA levels of indicated genes were performed 
by quantitative reverse transcription PCR analysis and normalized to actin. (b) Human CD3 +  T cells harbouring two or more IL2RA*T + IL7RA*C risk 
alleles (that is, IL2RA*T + IL7RA*C≥2) were pre-stimulated with anti-CD3 for 2 days (1 µg ml − 1) then treated with 100 nM 1,25(OH)2D3 for 3 days before 
fluorescence-activated cell sorting (FACS) analysis for L-PHA binding in CD4 +  cells. All donors are negative for MGAT1 IVAVT − T. Horizontal bar represents 
the average L-PHA MFI of each treatment group. (c) Human CD3 +  T cells lacking the IL2RA*T and IL7RA*C risk alleles (that is, IL2RA*T + IL7RA*C = 0, 
common haplotype for MGAT1) were pre-stimulated with anti-CD3 (400 ng ml − 1) and pre-treated with sIL2RA/sIL7RA for 2 days before addition of 
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Error bars represent the range of biological replicates. (f) Mice consuming ~500–625 ng dietary vitamin D3 per day were injected with 100 ng 1,25(OH)2D3 
by intraperitoneal injection every other day for a total of three times. Splenocytes were collected 24 h after the last injection and analysed for L-PHA 
binding in the indicated cell types by FACS. n = 8 mice stained in triplicate with error bars representing standard error of biological replicates. CD11b + , 
macrophages; CD11c + , dendritic cells; CD49b + , NK cells; Error bars are standard error of triplicate or greater values unless otherwise stated.ARTICLE     
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in vivo in a dose- and time-dependent manner (Fig. 5d,e). Intra-
peritoneal injection of 1,25(OH)2D3 in female PL/J mice enhanced 
branching in CD4 +  T cells  >  CD8 +  T cells  >  B cells (B220 + ) but 
had  little  effect  in  CD11b +   cells  (macrophages),  CD11c +   cells   
(dendritic  cells)  or  CD49b +   cells  (NK  cells;  Fig.  5f).  Blocking 
branching with SW reversed 1,25(OH)2D3-induced T cell hypopro-
liferation in response to TCR stimulation (Fig. 6a). 1,25(OH)2D3 
enhanced CTLA-4 cell surface expression in PL/J mouse and human 
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Figure 6 | Vitamin D3 regulates T cell growth and EAE. (a) Purified mouse CD3 +  T cells were stained with CFSE, stimulated with plate-bound anti-CD3 
antibody in the presence or absence of 1,25(OH)2D3 (20 nM) for 3 days and analysed by fluorescence-activated cell sorting (FACS) for CFSE dilution/
proliferation in CD4 +  T cells. Horizontal bars mark the population of proliferating cells, with the percentage of proliferating cells noted above. (b) Purified 
human CD3 +  T cells (n = 8 donors per group) were pre-stimulated with plate-bound anti-CD3 for 2 days (1 µg ml − 1) then treated with 100 nM 1,25(OH)2D3 
for 3 days. CD25 + CD4 +  blasting T cells were analysed for surface CTLA-4 expression by FACS. Horizontal bar represents the average L-PHA MFI of each 
treatment group. P value determined by t-test. (c) Purified mouse CD3 +  T cells were stimulated with plate-bound anti-CD3 (250 ng ml − 1) in the presence 
or absence of 1,25(OH)2D3 (150 nM) for 5 days and analysed by FACS for internalization rates of cell surface CTLA-4 in CD4 +  T cells. (d) PL/J mice 
treated as indicated were immunized with MBP + CFA and examined daily for clinical EAE. 1,25(OH)2D3 of 100 ng was administered by intraperitoneal 
injection every other day starting at day  − 3. SW was provided in drinking water and reduced L-PHA staining ~50%. P values by Fisher’s exact t-test, 
***P < 0.0001. (e) Female mice were immunized with 100 µg MBP + CFA by intraperitoneal injection and after 10 days, splenocytes were collected and re-
stimulated in vitro with MBP in the presence or absence of 1,25(OH)2D3 and/or SW as indicated. Proliferation was assessed by CFSE dilution and analysed 
by FACS. Error bars are standard error of triplicate or greater values in all panels.ARTICLE
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T cell blasts (Fig. 6b and Supplementary Fig. S7a,b) and markedly 
reduced CTLA-4 endocytosis rates (Fig. 6c). Intraperitoneal injec-
tion of 1,25(OH)2D3 inhibited myelin basic protein (MBP)-induced 
EAE in PL/J female mice in the absence but not presence of SW 
in the drinking water (Fig. 6d), where SW reduced branching in 
CD4 +  T cells ~50% (Supplementary Fig. S7c). SW also reversed 
1,25(OH)2D3-induced hypoproliferation in MBP-stimulated T cells 
isolated from MBP-immunized PL/J mice (Fig. 6e). Thus, vitamin 
D3 promotes branching and CTLA-4 surface retention to suppress 
T cell growth and autoimmune demyelinating disease when Mgat1 
activity is suppressed, as occurs with the IL2RA*T and IL7RA*C 
risk alleles and in the C57BL/6 and PL/J mouse strains.
Discussion
Defining  how  environmental  factors  combine  with  genetic  risk 
at the molecular level to promote complex trait diseases such as 
MS has remained a great challenge. Here we suggest a unifying 
molecular  mechanism  in  MS,  whereby  multiple  environmental   
factors (sunlight/vitamin D3 and metabolism) converge with multi-
ple genetic variants (IL-7RA, IL-2RA, MGAT1 and CTLA-4) to dys-
regulate a final common pathway, Golgi N-glycosylation (Fig. 7).   
A  causal  role  for  defective  N-glycosylation  is  supported  by  the 
development  of  spontaneous  inflammatory  demyelination  and   
neurodegeneration in Mgat1 and/or Mgat5-deficient mice17,20, as 
well as the observed biological and genetic interactions that appear 
to differentially control N-glycosylation and MS risk. The ability of 
environmental factors such as vitamin D3/sunshine and/or metabo-
lism to directly compensate for genetic downregulation of branch-
ing is consistent with concordance rates in monozygotic twins of 
only ~30% and their lack of significant detectable genomic, epig-
enomic or transcriptome differences10,11. Therapeutic supplemen-
tation to N-glycan biosynthesis may serve as a simple therapy to 
suppress phenotypic expression of MS risk factors. Indeed, vitamin 
D3 (1,25(OH)2D3) and GlcNAc are orally active, rescue branching 
deficiency on mouse T cells in vivo and inhibit EAE and sponta-
neous  autoimmune  diabetes  in  mice16,38,40.  In  humans,  oral  Glc-
NAc improved disease in 8 of 12 children with treatment-resistant 
inflammatory bowel disease41.
Defective N-glycosylation likely promotes MS by multiple mech-
anisms. Reduced N-glycosylation lowers T cell activation thresh-
olds and surface expression of the autoimmune inhibitor CTLA-4, 
promoting loss of self-tolerance. Mgat1 dysfunction may expose 
cryptic mannose linkages on the cell surface of oligodendrocytes 
that mimic microbial and pathogen glycans, chronically activating 
innate immune responses42,43. Neurodegeneration in MS may arise 
from increased sensitivity to apoptotic stimuli. Indeed, targeted defi-
ciency of Mgat1 in neurons induces their apoptosis in vivo, whereas 
Mgat5 deficiency enhances spontaneous neurodegeneration along 
with inflammatory demyelination17,20. Thus, genetic and environ-
mental alterations in the N-glycosylation pathway likely synergize 
to promote MS through dysfunction of both immune (T cells, anti-
gen presenting cells) and target cells (oligodendrocytes, neurons).
IL2RA*T  (rs2104286),  IL7RA*C  (rs6897932)  and  vitamin  D3 
deficiency also associate with type 1 diabetes (T1D)28,44–46, whereas 
non-obese diabetic mice are deficient for branching in T cells but 
not B cells20. A second independent variant of IL2RA (rs11594656) 
also alters sIL2RA levels and associates with both MS and T1D28, 
but paradoxically in opposite directions. CTLA-4 Ala17 (rs231775) 
displays point association with T1D but not MS34,47. These consid-
erations imply that defective N-glycosylation likely also contrib-
utes to T1D risk; however, interactions between these variants and 
MGAT1 IV AVT − T may differ because of disparity in CTLA-4 Ala17 
(rs231775)  frequencies  between  T1D  and  MS.  Direct  affects  of 
branching deficiency on neuronal survival would also be expected 
to result in distinctive interactions in MS compared with T1D and 
other autoimmune diseases.
IL-7 and IL-2 both promote T cell growth, yet targeted defi-
ciencies of these pathways in mice induce immunodeficiency and 
spontaneous autoimmunity, respectively48,49. Our data suggest that 
by having opposing effects on branching in resting and activated T 
cells, IL-2 and IL-7 enhance T cell growth early by lowering branch-
ing and TCR activation thresholds but promote self-tolerance later 
by enhancing branching and CTLA-4 surface retention.
Before GWAS, many candidate gene studies proved unreliable. 
This failure likely arose from multiple issues such as very small 
sample size, lack of replication cohorts, poor selection of candidate 
genes (that is, no evidence for regulating spontaneous disease in 
animals) and association testing in the absence of detailed func-
tional characterization. We avoided these issues by initially ignor-
ing association testing and performing a detailed biological screen 
for functional variants that induce phenotypes causal of disease 
in mice. Critically, only the single variant with the greatest bio-
logical effect is selected for subsequent association testing in large 
cohorts. This reverse approach also avoids the problem of mul-
tiple hypothesis testing inherent to GWAS. Indeed, the P values 
we report (~10 − 5 to 10 − 7) are orders of magnitude better than the 
genome-wide significance level of ~5×10 − 8 that corrects to ~0.02 
after adjusting for multiple hypothesis testing in a typical GWAS 
with ~550,000 SNPs50.
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Figure 7 | A model for environmental and genetic dysregulation of 
N-glycosylation in multiple sclerosis. Environmental and genetic 
interaction converges on the Golgi N-glycan branching enzyme Mgat1 and 
N-glycosylation of CTLA-4 in T cell blasts. Both down- or upregulation of 
Mgat1 activity decrease branching by limiting N-glycan or UDP-GlcNAc 
substrate to downstream enzymes, respectively. (1) Soluble receptors 
associated with the IL2RA*T (rs2104286) and IL7RA*C (rs6897932) 
MS risk alleles antagonize IL-2 and IL-7 signalling, leading to (2) 
downregulation of Mgat1, decreased branching and CTLA-4 surface 
levels and increased MS risk. (3) Vitamin D3 signalling counteracts this 
by enhancing Mgat1, leading to increased branching, CTLA-4 surface 
expression and decreased MS risk. (4) The MGAT1 IVAVT–T haplotype 
(rs7726005, rs2070924, rs2070925) increases Mgat1, which decreases 
branching, CTLA-4 surface levels and increases MS risk conditional on (5) 
metabolic production of UDP-GlcNAc. (6) Combining genetic upregulation 
of Mgat1 by the MGAT1 IVAVT–T haplotype with genetic downregulation  
of Mgat1 by the IL2RA*T and IL7RA*C MS risk alleles optimizes Mgat1 
activity, thereby enhancing branching, CTLA-4 surface expression and 
mitigating MS risk. The CTLA-4 Thr17Ala (rs231775) variant modifies  
these interactions by controlling the number of N-glycans attached to 
CTLA-4, with the Thr17 allele doubling N-glycan number to promote 
CTLA-4 surface retention and reduce MS risk when combined with MGAT1 
IVAVT–T, IL2RA*TT and IL7RA*CC.ARTICLE     
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As the N-glycan branching pathway includes at least ~30 genes 
likely to also harbour variants that alter branching, the additive 
risk reported here probably underestimates the true magnitude of 
genetic dysregulation of N-glycosylation in MS. Indeed, the top hit 
in a recent GWAS for variants regulating disease severity in MS was 
MGAT5 (ref. 51). More broadly, our data suggest an alternative to 
the rare allele—common disease hypothesis by implicating genetic 
and environmental interaction of common factors that additively 
converge  to  disrupt  a  critical  biochemical  pathway  regulating   
disease.
Methods
Reagents and flow cytometry. Isolated PBMCs (Histopaque-1077; Sigma) were 
stimulated with soluble anti-CD3 (Biomeda). CD3 +  T cells purified by negative 
selection (RosetteSep, StemCell Technologies) were stimulated with plate-bound 
anti-CD3 (OKT3, eBioscience). CD25 +  cells were positively selected by EasySep 
(StemCell Technologies). Procedures with human subjects were approved by 
the Institutional Review Board of the University of California, Irvine. IL-2 
(stock#002252) and IL7RA (stock#002295) deficient mice (Jackson Laboratories) 
were used between 4 and 8 weeks of age. IL7R − / − Mgat5 − / −  mice were obtained 
by crossing IL7RA-deficient mice with C57BL/6 Mgat5 − / −  mice. All mice were 
selected randomly for experiments and approved by the Institutional Animal Care 
and Use Committee of the University of California, Irvine. IL2RA antagonist Ro26-
4550 (Calbiochem), anti-IL-2 (clone#5334), anti-IL-7 (clone#7417), rhIL2, rhIL7, 
sIL2RA, sIL7RA/Fc (R&D systems) and rmIL-2 (eBioscience) were used. Human 
cells were stained with anti-CD4, anti-CTLA-4, anti-CD69 (eBioscience) and/or 
L-PHA-FITC (Phaseolus Vulgaris Leukoagglutinin, Vector Labs) as previously 
described15,16,20. Intracellular pStat5 staining used anti-Stat5pY694 (BDPharmingen, 
clone#47). Mouse cells were stained with anti-CD4 (RM 4-5), anti-CD8 (53-6.7), 
anti-CTLA-4 (UC10-4B9), anti-CD69 (H1.2F3), anti-B220 (RA3-6B2), anti-CD11b 
(M1/70), anti-CD11c (N418) and anti-CD49b (DX5) (eBioscience). Proliferation 
was assessed by 3H-thymidine incorporation or 5,6-carboxyfluorescein diacetate 
succinimidyl ester (CFSE; Molecular Probes) at 1 µM in PBS (20 min, 4 °C) and 
stimulated with plate-bound anti-CD3e (2C11, eBioscience). Cells were cultured in 
RPMI-1640 media supplemented with 10% fetal bovine serum, 2 µM L-glutamine, 
100 U ml − 1 penicillin/streptomycin and 2 µM 2-mercaptoethanol. For CTLA-4 
internalization, cells were stained for surface CTLA-4 (30 min, 4 °C), washed, incu-
bated at 37 °C at indicated times, washed in cold fluorescence-activated cell sorting 
buffer or acid for 4 min (0.133 M citric acid, 0.0666 M sodium carbonate, pH3.3). 
% internalization = 100×(mean fluorescence intensity (MFI) acid wash/MFI PBS 
wash).
Quantitative real-time PCR and differential allelic expression. RNA from 
transfected Lec1 cells and human PBMCs/T cells isolated by RNeasy kit (Qiagen) 
were reverse-transcribed by M-MLV Reverse Transcriptase (Ambion) and 
analysed by real-time PCR using TaqMan Gene Expression Assays with MGAT1 
(Hs00159121_m1), MGAT4a (Hs00923412_m1), MGAT4b (Hs00365001_m1), 
MGAT5 (Hs00159136_m1), MAN1A1 (Hs00195458_m1), MAN1A2 (Hs00198611_
m1), MAN1C1 (Hs00220595_m1), MAN2A1 (Hs00159007_m1), MAN2A2 
(Hs00196172_m1), GAPDH (Hs9999905_m1), and ACTIN (Hs99999903_m1) 
primers (Applied Biosystems). Relative mRNA expression was determined by ∆∆Ct 
method and normalized for GAPDH or ACTIN expression. Differential allelic 
expression was performed using two competing TaqMan probes targeting the 
common and VT–T polymorphisms of MGAT1 in cDNA and genomic DNA isolated 
from two individuals heterozygous for MGAT1 IV AVT–T haplotype. Reference 
curves for analysing allelic ratios were generated using plasmid containing either 
common or VT–T haplotype.
DNA sequencing and SNP analysis. Exon2 of MGAT, including ~20–100 
nucleotides (nt) of intronic sequence at 5′ and 3′ ends, was PCR-amplified from 
genomic DNA isolated from PBMCs and sequenced by Seqwright. SNPs were identi-
fied from chromatograms and derived sequences. All previously unknown SNPs 
were sequenced in both directions at least once, and confirmed with TaqMan allelic 
discrimination assay (Applied Biosystems). SNP genotyping was performed using 
TaqMan Genotyping Assays (Applied Biosystems), except for the controls from the 
greater Toronto area, which used the Sequenom Mass Array platform for genotyping 
the two SNPs in MGAT1 VT − T (rs2070924 and rs2070925). These two MGAT1 VT − T 
SNPs are 10nt apart and were genotyped in all other cohorts using a custom TaqMan 
probe designed to detect both (sequence submitted to Applied Biosystems was 5′-
CCTCGCCCGCGTCTACGGTGCTCCCCAGCTGCAGGTGGAGAAAGTGA 
GGACCAATGACCGGAAGGAG[C/T]TGGGGGAGGT[G/T]CGGGTGCAG 
TATACGGGCAGGGACAGCTTCAAGGCTTTCGCCAAGGCTCTGGGTGT 
CATGGATGACCTTAAGTCGGGGGTTCCGAGAG-3′). MGAT1 IV A (rs7726005) 
was also genotyped using a custom TaqMan probe (sequence: 5′-CACTACCGCT 
GGGCGCTGGGCCAGGTCTTCCGGCAGTTTCGCTTCCCCGCGGCCGTGG 
TGGTGGAGGATGACCTGGAGGTGGCCCCGGACTTCTTCGAGTACTT 
TC[G/A]GGCCACCTATCCGCTGCTGAAGGCCGACCCCTCCCTGTGGTG 
CGTCTCGGCCTGGAATGACAACGGCAAGGAGCAGATGGTGGACGCCA 
GCAGGCCTGAGCTGCTCTA-3′). Accuracy of the custom TaqMan assays was 
confirmed by sequencing genomic DNA from seven subjects genotyped as hetero-
zygous for both IV A and VT − T and sequencing cloned genomic DNA. Moreover, 
sequenom genotyping of 1,387 subjects for the two separate SNPs in VT − T revealed 
100% concordance. Human subjects are defined as positive or negative for MGAT1 
IV AVT − T by genotyping IV A and VT − T polymorphisms. TaqMan Genotpying Assay 
primers for CTLA-4 (rs231775), IL-2RA (rs2104286) and IL-7R (rs6897932) are 
C___2415786_20, C__16095542_10 and C___2025977_10, respectively. The 
genotyping success rate for all five SNPs examined was  > 99% in all cohorts except 
for IL2RA in control cohort 2 (98.8%). Concordance for duplicate genotyping 
was determined by re-genotyping all five SNPs in 735 samples and revealed 100% 
concordance for all SNPs except CTLA-4 (99.46%).
Cloning of human MGAT1 and CTLA-4 variants. MGAT1 and CTLA-4 variants 
were cloned into pCMV-Script (Stratagene), which uses human cytomegalovirus 
immediate early promoter to drive expression in mammalian systems. For MGAT1, 
primers 5′-CCCCCATTTCCTCTACCTGT-3′ and 5′-CCCTCCCACTCATCT 
GCTTTC-3′ were used to PCR-amplify exon2 from genomic DNA of subjects with 
or without IV A and VT − T polymorphisms followed by sequencing of PCR products. 
Full-length cDNA clones for CTLA-4Thr17 and Ala17 from Mammalian Gene 
Collection (http://mgc.nci.nih.gov/) were subcloned into pCMV vector follow-
ing PCR amplification with primers 5′-TGAACACCGCTCCCATAAAG-3′ and 
5′-CCTCAGCTCTTGGAAATTGAA-3′. Genotypes were confirmed by allelic 
discrimination assay.
Transient transfections. Mgat1-defective Lec1 cells (1×105) seeded 24 h earlier 
were incubated (5 h, 37 °C) with 3 µg plasmid DNA and 15 µl LIPOFECTAMINE 
(Invitrogen) serum-free DMEM and cultured for 72 h. Cells were stained with l-
PHA-FITC (4 µg ml − 1) ± anti-human CTLA-4-PE (eBioscience; 30 min, 4 °C); MFIs 
determined on L-PHA +  population.
Enzymatic assays. Mgat1 enzyme activity was measured using the synthetic, 
specific acceptor αMan(1,3)βMan-O(CH2)7CH3 (Toronto Research Chemicals). 
Avolume of 10 µl cell lysate (0.9% NaCl, 1% Triton X-100, centrifuged 5,000 g, 
15 min, 4 °C) was added to 1 mM acceptor, 1 mM [63H]-UDP-GlcNAc (Amer-
sham) in 50 mM MES pH6.5, 0.1 mM GlcNAc and 25 mM AMP in total of 20 µl. 
Mgat1 reactions containing 5 mM MnCl2, were incubated for 1 h and stopped 
with ice-cold water. Enzyme products were separated from radioactive substrates 
by binding to 50 mg C18 cartridges (Alltech) preconditioned with methanol 
rinsing/water washing. Radiolabelled products were eluted directly into scintilla-
tion vials with two 0.5 ml aliquots of methanol; radioactivity was determined by 
liquid scintillation counting.
Matrix-assisted laser desorption/ionization–time of flight mass spectros-
copy. This was done as a service by Glycotechnology Core Facility at University 
of California, San Diego. PBMCs were lysed with 1% SDS in 100 mM Tris, pH7.4, 
dialysed to remove SDS, digested with trypsin to generate glycopeptides and 
treated with PNGaseF to release N-glycans. N-glycans were desialylated by mild 
acid digestion before permethylation and mass spectroscopy. Monoisotopic peaks 
were identified using GlycanMass/GlycoMod software.
Computational model. Computational modelling of Golgi N-glycan processing 
and lattice-mediated glycoprotein surface retention was previously described15. 
Briefly, biochemical reaction network for N-glycan processing was represented by a 
series of ordinary differential equations constructed using generalized mass action 
formulation and generated structures up to a maximum size of tetra-antennary 
with N-acetyllactosamine and (Galβ1-4GlcNAcβ1-3)2 extensions. The fraction of 
each N-glycan type was used to calculate the glycoform fractions of CTLA-4 in a 
combinatorial manner dependent on number of N-glycosylation sites. Glycoform 
avidity for galectin lattice is represented as a linear summation of the affinity of 
each N-glycan, with avidity enhancements as described previously.
Vitamin D3 and experimental autoimmune encephalomyelitis. To induce 
in vivo deficiency of vitamin D3, age-matched littermate female PL/J mice were 
randomly selected and fed 4 g per day of chow containing varying amounts of 
vitamin D3 (500–625 ng, 250 ng, 125 ng; Prolab RMH 2,500, LabDiet) or a diet de-
ficient in vitamin D3 (0 ng; specially formulated for our laboratory) for 5–21 days. 
1,25(OH)2D3 (100 ng) was administered in vivo to age-matched littermate female 
PL/J mice (fed diet containing 500–625 ng vitamin D3) by intraperitoneal injection 
every other day for the duration of the study. EAE was induced by subcutaneous 
immunization of randomly selected female PL/J mice at days 0 and 15 with 100 µg 
of bovine MBP (Sigma) emulsified in Complete Freund’s Adjuvant containing 
4 mg ml − 1 heat-inactivated Mycobacterium tuberculosis (H37RA;Difco). Mice 
were examined daily for clinical signs of EAE over the next 40 days with observer 
blinded to treatment conditions. Mice were scored daily as follows: 0, no disease; 
1, loss of tail tone; 2, hindlimb weakness; 3, hindlimb paralysis; 4, forelimb weak-
ness or paralysis and hindlimb paralysis; 5, moribund or dead. All EAE mice were ARTICLE
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maintained on a diet low in calcium and vitamin D3 (Certified Rodent Diet 5002*, 
LabDiet). 1,25(OH)2D3 of 100 ng was administered by intraperitoneal injection 
every other day and SW was given orally via the drinking water starting 3 days 
before immunization. All mice were housed with 12-h light/dark cycles.
DNA datasets. We analysed two independent randomly selected non-Hispanic 
Caucasian MS case–control cohorts and an African-American MS cohort from 
North America. Cohort 1 cases consisted of unrelated, non-Hispanic Caucasians 
with clinically definite MS52 obtained at University of California, Irvine (n = 82) or 
from across the United States by Multiple Autoimmune Disease Genetics Consor-
tium (n = 176, http://www.madgc.org) and Accelerated Cure Project for Multiple 
Sclerosis (n = 943, http://www.acceleratedcure.org). Controls were unrelated, 
non-diabetic, non-Hispanic, Caucasians obtained at University of California, 
Irvine (n = 102) and from across North America by North American Rheumatoid 
Arthritis Consortium (n = 192, NARAC, http://www.naracdata.org) and Type1 
Diabetes Genetics Consortium (n = 1,199, http://www.t1dgc.org). Cohort 2 cases 
were unrelated, non-Hispanic Caucasians with clinically definite MS obtained from 
across United States by BioServe (n = 1,030, http://www.bioserve.com) and Univer-
sity of California, San Francisco (n = 1,050). Cohort 2 controls were non-diabetic, 
non-Hispanic and unrelated Caucasians obtained from across North America  
(BioServe (n = 2,972), Genetics of Kidneys in Diabetes (GoKinD; n = 746, 
http://www.niddkrepository.org), NARAC (n = 1,159), UCSF (n = 796) and greater 
Toronto area (n = 1,387). GoKinD DNA samples were obtained from National  
Institute of Diabetes and Digestive and Kidney Diseases. The African-American 
MS cohort has previously been described53 and comprises 758 unrelated MS  
patients and 480 unrelated controls. All study participants are self-reported 
African-Americans, but European ancestry was documented in the majority of 
individuals based on genotyping of 186 SNPs highly informative for African versus 
European ancestry. Global estimation of European ancestry using these markers 
indicated similar mean admixture proportions in cases and controls (21%). Indi-
vidual and combined control cohorts were in Hardy Weinberg Equilibrium. 
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